218 related articles for article (PubMed ID: 37040113)
21. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system.
Scosyrev E; Wu G; Golijanin D; Messing E
BJU Int; 2012 Nov; 110(10):1485-90. PubMed ID: 22448649
[TBL] [Abstract][Full Text] [Related]
23. National evidence on the use of shared decision making in prostate-specific antigen screening.
Han PK; Kobrin S; Breen N; Joseph DA; Li J; Frosch DL; Klabunde CN
Ann Fam Med; 2013; 11(4):306-14. PubMed ID: 23835816
[TBL] [Abstract][Full Text] [Related]
24. Changes in Health Care Access and Preventive Health Screenings by Race and Ethnicity.
Alba C; Zheng Z; Wadhera RK
JAMA Health Forum; 2024 Feb; 5(2):e235058. PubMed ID: 38306093
[TBL] [Abstract][Full Text] [Related]
25. Patient perspectives of prostate cancer screening vary by race following 2018 guideline changes.
Riviere P; Kalavacherla S; Banegas MP; Javier-Desloges J; Martinez ME; Garraway IP; Murphy JD; Rose BS
Cancer; 2023 Jan; 129(1):82-88. PubMed ID: 36345568
[TBL] [Abstract][Full Text] [Related]
26. Racial and Ethnic Disparities in the Use of Prostate Magnetic Resonance Imaging Following an Elevated Prostate-Specific Antigen Test.
Abashidze N; Stecher C; Rosenkrantz AB; Duszak R; Hughes DR
JAMA Netw Open; 2021 Nov; 4(11):e2132388. PubMed ID: 34748010
[TBL] [Abstract][Full Text] [Related]
27. Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States.
Kim SP; Karnes RJ; Gross CP; Meropol NJ; Van Houten H; Abouassaly R; Shah ND
Urology; 2016 Nov; 97():111-117. PubMed ID: 27527411
[TBL] [Abstract][Full Text] [Related]
28. What Have Patients Been Hearing From Providers Since the 2012 USPSTF Recommendation Against Routine Prostate Cancer Screening?
Haider MR; Qureshi ZP; Horner R; Friedman DB; Bennett C
Clin Genitourin Cancer; 2017 Dec; 15(6):e977-e985. PubMed ID: 28625690
[TBL] [Abstract][Full Text] [Related]
29. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
[TBL] [Abstract][Full Text] [Related]
30. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?
Sirovich BE; Schwartz LM; Woloshin S
JAMA; 2003 Mar; 289(11):1414-20. PubMed ID: 12636464
[TBL] [Abstract][Full Text] [Related]
31. Low-Value Prostate Cancer Screening Among Older Men Within the Veterans Health Administration.
Radomski TR; Huang Y; Park SY; Sileanu FE; Thorpe CT; Thorpe JM; Fine MJ; Gellad WF
J Am Geriatr Soc; 2019 Sep; 67(9):1922-1927. PubMed ID: 31276198
[TBL] [Abstract][Full Text] [Related]
32. Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities.
Bryant AK; Lee KM; Alba PR; Murphy JD; Martinez ME; Natarajan L; Green MD; Dess RT; Anglin-Foote TR; Robison B; DuVall SL; Lynch JA; Rose BS
JAMA Oncol; 2022 Dec; 8(12):1747-1755. PubMed ID: 36279204
[TBL] [Abstract][Full Text] [Related]
33. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen screening among young men in the United States.
Scales CD; Antonelli J; Curtis LH; Schulman KA; Moul JW
Cancer; 2008 Sep; 113(6):1315-23. PubMed ID: 18696715
[TBL] [Abstract][Full Text] [Related]
35. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
36. Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending.
Kim DD; Daly AT; Koethe BC; Fendrick AM; Ollendorf DA; Wong JB; Neumann PJ
JAMA Netw Open; 2022 Nov; 5(11):e2243449. PubMed ID: 36413364
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Care Cascades Following Low-Value Prostate-Specific Antigen Testing Among Veterans Dually Enrolled in the US Veterans Health Administration and Medicare Systems.
Pickering AN; Zhao X; Sileanu FE; Lovelace EZ; Rose L; Schwartz AL; Oakes AH; Hale JA; Schleiden LJ; Gellad WF; Fine MJ; Thorpe CT; Radomski TR
JAMA Netw Open; 2022 Dec; 5(12):e2247180. PubMed ID: 36520431
[TBL] [Abstract][Full Text] [Related]
38. Investigating the racial gap in prostate cancer screening with prostate-specific antigen among younger men from 2012 to 2020.
Qian Z; Al Khatib K; Chen X; Belani S; Labban M; Lipsitz S; Cole AP; Iyer HS; Trinh QD
JNCI Cancer Spectr; 2023 Mar; 7(2):. PubMed ID: 36708009
[TBL] [Abstract][Full Text] [Related]
39. Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era.
Sammon JD; Dalela D; Abdollah F; Choueiri TK; Han PK; Hansen M; Nguyen PL; Sood A; Menon M; Trinh QD
J Urol; 2016 Apr; 195(4 Pt 1):913-8. PubMed ID: 26598427
[TBL] [Abstract][Full Text] [Related]
40. Multilevel Small Area Estimation of Prostate-Specific Antigen Screening Test in the United States by Age Group: 2018 Behavioral Risk Factor Surveillance System.
Berkowitz Z; Zhang X; Richards TB; Sabatino SA; Peipins LA; Smith JL
J Am Board Fam Med; 2021; 34(3):634-647. PubMed ID: 34088823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
